Abstrakt

Przypisy

• 1. Aronson D.C., Schnater J.M., Staalman C.R., Weverling G.J., PlaschkesJ., Perilongo G., Brown J., Phillips A., Otte J.B., Czauderna P.,MacKinlay G., Vos A.: Predictive value of the pretreatment extentof disease system in hepatoblastoma: results from the InternationalSociety of Pediatric Oncology Liver Tumor Study Group SIOPEL-1study. J. Clin. Oncol., 2005; 23: 1245-1252
  Google Scholar
• 2. Boriosi J..P, Maki D.G., Yngsdal-Krenz R.A., Wald E.R., Porter W.P.,Cook M.E., Bütz D.E.: Changes in breath carbon isotope compositionas a potential biomarker of inflammatory acute phase response inmechanically ventilated pediatric patients. J. Anal. At. Spectrom.,2014; 29: 599-605
  Google Scholar
• 3. Bulterys M., Goodman M.T., Smith M.A., Buckley J.D.: Hepatic tumors.In: Cancer incidence and survival among children and adolescents:United States SEER Program 1975-1995. Eds.: Ries L.A., SmithM.A., Gurney J.G., Linet M., Tamra T., Young J.L. Bunin G.R., Bethesda,MD: National Cancer Institute, SEER Program, 1999. NIH Pub.No. 99-4649, 91-98
  Google Scholar
• 4. Carter J.F., Barwick V.J. (ed.).: Good practice guide for isotoperatio mass spectrometry. FIRMS 2011. http://www.forensic-isotopes.org/gpg.html
  Google Scholar
• 5. Conran R.M., Hitchcock C.L., Waclawiw M.A., Stocker J.T., IshakK.G.: Hepatoblastoma: the prognostic significance of histologic type.Pediatr. Pathol., 1992; 12: 167-183
  Google Scholar
• 6. Darbari A., Sabin K.M., Shapiro C.N., Schwarz K.B.: Epidemiologyof primary hepatic malignancies in U.S. children. Hepatology,2003; 38: 560-566
  Google Scholar
• 7. Douglass E.C., Reynolds M., Finegold M., Cantor A.B., GlicksmanA.: Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma:a Pediatric Oncology Group study. J. Clin. Oncol., 1993; 11: 96-99
  Google Scholar
• 8. Fuchs J., Rydzynski J., Von Schweinitz D., Bode U., Hecker H.,Weinel P., Bürger D., Harms D., Erttmann R., Oldhafer K., MildenbergerH. and the Study Committee of the Cooperative PediatricLiver Tumor Study Hb 94 for the German Society for the PediatricOncology and Hematology: Pretreatment prognostic factors andtreatment results in children with hepatoblastoma: a report fromthe German Cooperative Pediatric Liver Tumor Study HB 94. Cancer,2002; 95: 172-182
  Google Scholar
• 9. Fuller B.T., Fuller J.L., Sage N.E., Harris D.A., O’Connell T.C., HedgesR.E.: Nitrogen balance and δ15N: why you’re not what you eat duringnutritional stress. Rapid Commun. Mass Spectrom., 2005; 19:2497-2506
  Google Scholar
• 10. Haas J.E., Muczynski K.A., Krailo M., Ablin A., Land V., ViettiT.J., Hammond G.D.: Histopathology and prognosis in childhoodhepatoblastoma and hepatocarcinoma. Cancer, 1989; 64: 1082-1095
  Google Scholar
• 11. Herzog C.E., Andrassy R.J., Eftekhari F.: Childhood cancers: hepatoblastoma.The Oncologist, 2000; 5: 445-453
  Google Scholar
• 12. Howlader N., Noone A.M., Krapcho M., Neyman N., Aminou R.,Waldron W.: Childhood cancer by the ICCC. SEER Cancer StatisticsReview, 1975-2009 (Vintage 2009 Populations). Bethesda, MD: NationalCancer Institute, 2012, Section 29
  Google Scholar
• 13. Koch A., Waha A., Hartmann W., Hrychyk A., Schuller U., WahaA., Wharton K.A.Jr., Fuchs S.Y., von Schweinitz D., Pietsch T.: Elevatedexpression of Wnt antagonists is a common event in hepatoblastomas.Clin. Cancer Res., 2005; 11: 4295-4304
  Google Scholar
• 14. Macko S., Estep M.L., Engel M.H., Hare P.E.: Kinetic fractionationof stable nitrogen isotopes during amino acid transamination. Geochim.Cosmochim. Acta, 1986; 50: 2143-2146
  Google Scholar
• 15. Macko S., Fogel M.L., Hare P.E., Hoering T.C.: Isotopic fractionationof nitrogen and carbon in the synthesis of amino acids by microorganisms.Chem. Geology, 1987; 65: 79-92
  Google Scholar
• 16. McLaughlin C.C., Baptiste M.S., Schymura M.J., Nasca P.C., ZdebM.S.: Maternal and infant birth characteristics and hepatoblastoma.Am. J. Epidemiol., 2006; 163: 818-828
  Google Scholar
• 17. Mekota A.M., Grupe G., Ufer S., Cuntz U.: Serial analysis of stablenitrogen and carbon isotopes in hair: monitoring starvation and recoveryphases of patients suffering from Anorexia nervosa. RapidCommun. Mass Spectrom., 2006; 20: 1604-1610
  Google Scholar
• 18. Meyers R.L., Rowland J.R., Krailo M., Chen Z., Katzenstein H.M.,Malogolowkin M.H.: Predictive power of pretreatment prognosticfactors in children with hepatoblastoma: a report from the Children’sOncology Group. Pediatr. Blood Cancer, 2009; 53: 1016-1022
  Google Scholar
• 19. Nakagawara A., Ikeda K., Tsuneyoshi M., Daimaru Y., Enjoji M.,Watanabe I., Iwafuchi M., Sawada T.: Hepatoblastoma producing bothα-fetoprotein and human chorionic gonadotropin. Clinicopathologicanalysis of four cases and a review of the literature. Cancer,1985; 56: 1636-1642
  Google Scholar
• 20. Ortega J.A., Douglass E.C., Feusner J.H., Reynolds M., Quinn J.J.,Finegold M.J., Haas J.E., King D.R., Liu-Mares W., Sensel M.G., KrailoM.D.: Randomized comparison of cisplatin/vincristine/fluorouraciland cisplatin/continuous infusion doxorubicin for treatment of pediatrichepatoblastoma: a report from the Children’s Cancer Groupand the Pediatric Oncology Group. J. Clin. Oncol., 2000; 18: 2665-2675
  Google Scholar
• 21. Otte J.B., Pritchard J., Aronson D.C., Brown J., Czauderna P., MaibachR., Perilongo G., Shafford E., Plaschkes J.; International Societyof Pediatric Oncology (SIOP): Liver transplantation for hepatoblastoma:results from the International Society of Pediatric Oncology(SIOP) study SIOPEL-1 and review of the world experience. Pediatr.Blood Cancer, 2004; 42: 74-83
  Google Scholar
• 22. Perilongo G., Malogolowkin M., Feusner J.: Hepatoblastoma clinicalresearch: lessons learned and future challenges. Pediatr. BloodCancer, 2012; 59: 818-821
  Google Scholar
• 23. Peterson B.J., Fry B.: Stable isotopes in ecosystem studies. Ann.Rev. Ecol. Syst., 1987; 1: 293-320
  Google Scholar
• 24. Sandberg P.A., Loudon J.E., Sponheimer M.: Stable isotope analysisin primatology: a critical review. Am. J. Primatol., 2012; 74: 969-989
  Google Scholar
• 25. Schneider D.T., Calaminus G., Göbel U.: Diagnostic value of α1-fetoprotein and β-human chorionic gonadotropin in infancy andchildhood. Pediatr. Hematol. Oncol., 2001; 18: 11-26
  Google Scholar
• 26. Stocker J.T.: Hepatoblastoma. Semin. Diagn. Pathol., 1994; 11:136-143
  Google Scholar
• 27. Tan X., Apte U., Micsenyi A., Kotsagrelos E., Luo J.H., RanganathanS., Monga D.K., Bell A., Michalopoulos G.K., Monga S.P.: Epidermalgrowth factor receptor: a novel target of the Wnt/β-cateninpathway in liver. Gastroenterology, 2005; 129: 285-302
  Google Scholar
• 28. Tanimura M., Matsui I., Abe J., Ikeda H., Kobayashi N., Ohira M.,Yokoyama M., Kaneko M.: Increased risk of hepatoblastoma amongimmature children with a lower birth weight. Cancer Res., 1998;58: 3032-3035
  Google Scholar
• 29. Taran K.: Izotopowa spektrometria mas jako nowe narzędziew badaniach patomechanizmów choroby nowotworowej z uwzględnieniemmapy izotopowej organizmów dzieci w regionie łódzkim.Uniwersytet Medyczny w Łodzi, Łódź 2015: 88-191
  Google Scholar
• 30. Taran K., Frączek T., Kamiński R., Sitkiewicz A., Kobos J., PanethP.: The first protocol of stable isotope ratio assessment in tumortissues based on original research. Pol. J. Pathol., 2015; 66: 288-295
  Google Scholar
• 31. Taran K., Frączek T., Sitkiewicz A., Paneth P., Kobos J.,: Rhabdomyosarcomain children in the light of isotope ratio mass spectrometry.Pol. J. Pathol., 2015; 66: 383-388
  Google Scholar
• 32. Trobaugh-Lotrario A.D., Katzenstein H.M.: Chemotherapeuticapproaches for newly diagnosed hepatoblastoma: past, present, andfuture strategies. Pediatr. Blood Cancer, 2012; 59: 809-812
  Google Scholar
• 33. Turcotte L.M., Georgieff M.K., Ross J.A., Feusner J.H., TomlinsonG.E., Malogolowkin M.H., Krailo M.D., Miller N., Fonstad R., SpectorL.G.: Neonatal medical exposures and characteristics of low birthweight hepatoblastoma cases: a report from the Children’s OncologyGroup. Pediatr. Blood Cancer, 2014; 11: 2018-2023
  Google Scholar
• 34. Warmann S., Hunger M., Teichmann B., Flemming P., Gratz K.F.,Fuchs J.: The role of the MDR1 gene in the development of multidrugresistance in human hepatoblastoma: clinical course and in vivomodel. Cancer, 2002; 95: 1795-1801
  Google Scholar
• 35. Wirths O., Waha A., Weggen S., Schirmacher P., Kühne T., GoodyerC.G., Albrecht S., Von Schweinitz D., Pietsch T.: Overexpressionof human Dickkopf-1, an antagonist of wingless/WNT signaling,in human hepatoblastomas and Wilms’ tumors. Lab. Invest., 2003,83: 429-434
  Google Scholar
• 36. Zsíros J., Maibach R., Shafford E., Brugieres L., Brock P., CzaudernaP., Roebuck D., Childs M., Zimmermann A., Laithier V., Otte J.B.,de Camargo B., MacKinlay G., Scopinaro M., Aronson D., PlaschkesJ., Perilongo G.: Successful treatment of childhood high-risk hepatoblastomawith dose-intensive multiagent chemotherapy andsurgery: final results of the SIOPEL-3HR study. J. Clin. Oncol., 2010;28: 2584-2590
  Google Scholar

Pełna treść artykułu